To view and print the document you may need to install the latest version of the free Acrobat Reader software. If you do not currently have the latest version please click here.
Founded in 1949, Ethicon is best known as the world's leading suture company. Since then, the company has focused its expertise of understanding the complex ways in which biomaterials interact with the tissue of the human body to create a portfolio of products that advance healthcare across several areas including: wound closure; hernia surgery; biosurgery; women’s health and aesthetics. The latest addition to complement these businesses is products in the ear, nose and throat (ENT) sector.
Wound closure includes the world’s largest portfolio of synthetic sutures, PLUS Coated Antibacterial sutures and Dermabond Topical Skin Adhesive.
Hernia solutions includes a portfolio of mesh for use in hernia repair including Proceed Surgical Mesh, PhysioMesh Flexible Composite Mesh and the recently-approved SecureStrap 5mm Strap Fixation Device, which represented the company's first entry into the hernia mesh fixation market.
Women’s health includes what is claimed to be the largest portfolio of products on the market for conditions including incontinence, pelvic floor prolapse and for use in uterine surgery. These products are sold under the Gynecare brand.
Biosurgery comprises a portfolio of options for surgical haemostasis, which was expanded in 2008 with the acquisition of Omrix Biopharmaceuticals. Products include Evicel Fibrin Sealant (Human) and Omnex Surgical Sealant, the company's first synthetic internal-use sealant, while its Biopatch product offers infection-resistant wound dressings.
Aesthetics, capitalising on the 2009 acquisition of breast implant leader Mentor, which now reports as a business unit of Ethicon. Mentor also produces other plastic surgery products and expanded into the facial surgical aesthetics market with the launch of the PDS Flexible Plate, an absorbable implant that provides structural support and streamlines cartilage management during nasal reconstruction procedures.
ENT, an area of focus through the 2010 acquisition of Acclarent, whose Balloon Sinuplasty procedure provides an alternative to the current standard of care for patients who suffer from symptoms of chronic rhinosinusitis.
Ethicon has its headquarters in Somerville, New Jersey, US. It also has facilities in Georgia, Texas, and North Carolina in the US; Auneau, France; Aurangabad and Dharavi (Mumbai), India; Juarez, Mexico; Kirkton (Scotland) and Gargrave, UK; Neuchatel, Switzerland; Norderstedt, Germany; San Lorenzo, Puerto Rico; Sao Jose dos Campos, Brazil; Kiryat-Ono, Israel; and Shanghai, China.
In 2011, Ethicon generated sales of almost US$4.9 billion and employed approximately 8,500 people.
This company report provides
Overview
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format
Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
